Who makes HRS-8080; SHR-A1811?

HRS-8080; SHR-A1811 is developed by Shandong Suncadia Medicine Co., Ltd..

What development phase is HRS-8080; SHR-A1811 in?

HRS-8080; SHR-A1811 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

HRS-8080; SHR-A1811

Shandong Suncadia Medicine Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	HRS-8080; SHR-A1811
Sponsor	Shandong Suncadia Medicine Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HRS-8080; SHR-A1811 CI brief — competitive landscape report
HRS-8080; SHR-A1811 updates RSS · CI watch RSS
Shandong Suncadia Medicine Co., Ltd. portfolio CI